Drug Trial Radar · NCT03344159
Spironolactone Therapy in Chronic Stable Right HF Trial
Last checked: Nov 21, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Apr 1, 2018
Primary completion
Aug 30, 2022
Study completion May 1, 2024
Sponsor
- Lead sponsor
- Ottawa Heart Institute Research CorporationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.
Conditions
- Chronic Right-Sided Heart Failure
- Pulmonary Arterial Hypertension
- Pulmonary Hypertension, Primary, 2
- Pulmonary Hypertension, Primary, 3
- Pulmonary Hypertension, Primary, 4
- Cardiomyopathy Right Ventricular
Interventions
SpironolactoneDrug
Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
PlaceboDrug
Placebo daily for a total of duration of 12 weeks
PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82Radiation
At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
Cardiac MRI (Gadolinium enhanced)Diagnostic test
At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Ventricular Wall StressTime frame: Baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.